These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 8946476)

  • 1. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
    Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L
    Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
    Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
    Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
    Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
    Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
    Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
    Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
    Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
    Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
    Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
    Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL; Huang JD; Lai MD; Liu BH; Lai ML
    Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
    Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
    Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
    Ford GA; Wood SM; Daly AK
    Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.